Cargando…

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection

Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Victor Chien-Chia, Li, Yan-Rong, Wang, Chao-Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268177/
https://www.ncbi.nlm.nih.gov/pubmed/34281221
http://dx.doi.org/10.3390/ijms22137170
_version_ 1783720300846776320
author Wu, Victor Chien-Chia
Li, Yan-Rong
Wang, Chao-Yung
author_facet Wu, Victor Chien-Chia
Li, Yan-Rong
Wang, Chao-Yung
author_sort Wu, Victor Chien-Chia
collection PubMed
description Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin. This class of drugs has the advantages of no clinically relevant hypoglycemia and working in synergy when combined with currently available anti-diabetic drugs. While improving sugar level control in these patients, SGLT2 inhibitors also have the advantages of blood-pressure improvement and bodyweight reduction, with potential cardiac and renal protection. In randomized control trials for patients with diabetes, SGLT2 inhibitors not only improved cardiovascular and renal outcomes, but also hospitalization for heart failure, with this effect extending to those without diabetes mellitus. Recently, dynamic communication between autophagy and the innate immune system with Beclin 1-TLR9-SIRT3 complexes in response to SGLT2 inhibitors that may serve as a potential treatment strategy for heart failure was discovered. In this review, the background molecular pathways leading to the clinical benefits are examined in this new class of anti-diabetic drugs, the SGLT2 inhibitors.
format Online
Article
Text
id pubmed-8268177
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82681772021-07-10 Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection Wu, Victor Chien-Chia Li, Yan-Rong Wang, Chao-Yung Int J Mol Sci Review Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin. This class of drugs has the advantages of no clinically relevant hypoglycemia and working in synergy when combined with currently available anti-diabetic drugs. While improving sugar level control in these patients, SGLT2 inhibitors also have the advantages of blood-pressure improvement and bodyweight reduction, with potential cardiac and renal protection. In randomized control trials for patients with diabetes, SGLT2 inhibitors not only improved cardiovascular and renal outcomes, but also hospitalization for heart failure, with this effect extending to those without diabetes mellitus. Recently, dynamic communication between autophagy and the innate immune system with Beclin 1-TLR9-SIRT3 complexes in response to SGLT2 inhibitors that may serve as a potential treatment strategy for heart failure was discovered. In this review, the background molecular pathways leading to the clinical benefits are examined in this new class of anti-diabetic drugs, the SGLT2 inhibitors. MDPI 2021-07-02 /pmc/articles/PMC8268177/ /pubmed/34281221 http://dx.doi.org/10.3390/ijms22137170 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wu, Victor Chien-Chia
Li, Yan-Rong
Wang, Chao-Yung
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
title Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
title_full Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
title_fullStr Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
title_full_unstemmed Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
title_short Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
title_sort impact of sodium–glucose co-transporter 2 inhibitors on cardiac protection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268177/
https://www.ncbi.nlm.nih.gov/pubmed/34281221
http://dx.doi.org/10.3390/ijms22137170
work_keys_str_mv AT wuvictorchienchia impactofsodiumglucosecotransporter2inhibitorsoncardiacprotection
AT liyanrong impactofsodiumglucosecotransporter2inhibitorsoncardiacprotection
AT wangchaoyung impactofsodiumglucosecotransporter2inhibitorsoncardiacprotection